COVID-19 Vaccine Effectiveness Against Hospitalization and Mortality Among Children and Young People with Obesity: A Population-Based Cohort Study
Vaccines · 20.11.2026 · 14 (11) · 1004
DOI: 10.3390/vaccines14111004 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Vaccines, online erschienen am 20.11.2026. Verfasst von Laura G. Coelho und 13 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brazilian agencies: CNPq, FAPEMIG, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background/Objectives: We investigated COVID-19-related outcomes and the real-world effectiveness of COVID-19 vaccination against hospitalization and death among children, adolescents, and young people (CYP) with obesity.
Methods
In this nationwide population-based retrospective cohort study, we analyzed CYP (2–25 years) with laboratory-confirmed COVID-19 recorded in the official Brazilian national surveillance databases between February 2020 and December 2025. For the analysis, the sample was divided into two cohorts according to the presence of obesity. The outcomes of interest were COVID-19-related hospitalization and death. Vaccine effectiveness (VE) against hospitalization and death was estimated using multivariable logistic regression models. The number needed to vaccinate (NNV) to prevent one outcome was estimated in a propensity score-matched cohort, with adjustments for confounders.
Results
The cohort comprised 6,904,083 individuals with COVID-19, including 18,149 individuals with obesity (0.3%). After controlling for confounding factors, patients with obesity were at a higher risk of hospitalization (OR = 3.7, 95% CI, 2.6–5.3) and death (OR = 2.1, 95% CI, 1.9–2.3) compared with those without obesity. The estimated VE against death due to SARS-CoV-2 infection for fully vaccinated individuals was 54.1% (95% CI 50.9–57.2) and 71.5% (95% CI 63.0–78.1%) for the non-obesity and obesity cohorts, respectively. After matching, it was estimated that the NNV to prevent one death was 10 (95% CI, 7–14) for CYP with obesity associated with other comorbidities and 25 (95% CI, 20–45) for those without comorbidities. In contrast, the respective figures for the non-obesity cohort were 117 (95% CI, 99–142) and 2168 (95% CI, 1362–2567) for those with and without comorbidities.
Conclusions
CYP with obesity had a higher risk of death than those without obesity. Vaccination was associated with lower risks of hospitalization and death among vaccinated individuals with obesity, reinforcing the importance of prioritizing this high-risk group.
Förderung
- Brazilian agencies: CNPq
- FAPEMIG
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Coelho, L. G., Diniz, L. M., Galante, S. C., Oliveira, F. E. S., Silva, A. C. S. E., Dias, C. S., Colosimo, E. A., Martelli-Júnior, H., Martelli, D. R. B., Bernardes, M. E. T., Santos, A. L., Mak, R. H., Oliveira, M. C. L., & Oliveira, E. A. (2026). COVID-19 Vaccine Effectiveness Against Hospitalization and Mortality Among Children and Young People with Obesity: A Population-Based Cohort Study. Vaccines, 14(11), 1004. https://doi.org/10.3390/vaccines14111004
Vancouver
Coelho LG, Diniz LM, Galante SC, Oliveira FES, Silva ACSE, Dias CS, et al. COVID-19 Vaccine Effectiveness Against Hospitalization and Mortality Among Children and Young People with Obesity: A Population-Based Cohort Study. Vaccines. 2026;14(11):1004. doi:10.3390/vaccines14111004
BibTeX
@article{Coelho2026,
author = {Coelho, Laura G. and Diniz, Lilian M. and Galante, Stella C. and Oliveira, Fabrício Emanuel S. and Silva, Ana Cristina Simoes e and Dias, Cristiane S. and Colosimo, Enrico A. and Martelli-Júnior, Hercílio and Martelli, Daniella R. B. and Bernardes, Maria Eduarda T. and Santos, Adriano L. and Mak, Robert H. and Oliveira, Maria Christina L. and Oliveira, Eduardo A.},
title = {COVID-19 Vaccine Effectiveness Against Hospitalization and Mortality Among Children and Young People with Obesity: A Population-Based Cohort Study},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {1004},
doi = {10.3390/vaccines14111004}
}
EUVIMED